Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity.

Hernandez-Sanchez W, Huang W, Plucinsky B, Garcia-Vazquez N, Robinson NJ, Schiemann WP, Berdis AJ, Skordalakes E, Taylor DJ.

PLoS Biol. 2019 Apr 5;17(4):e3000204. doi: 10.1371/journal.pbio.3000204. eCollection 2019 Apr.

2.

Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.

Vaidya AM, Sun Z, Ayat N, Schilb A, Liu X, Jiang H, Sun D, Scheidt J, Qian V, He S, Gilmore H, Schiemann WP, Lu ZR.

Bioconjug Chem. 2019 Mar 20;30(3):907-919. doi: 10.1021/acs.bioconjchem.9b00028. Epub 2019 Feb 21.

PMID:
30739442
3.

The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers.

Gooding AJ, Zhang B, Gunawardane L, Beard A, Valadkhan S, Schiemann WP.

Oncogene. 2019 Mar;38(12):2020-2041. doi: 10.1038/s41388-018-0586-4. Epub 2018 Nov 22.

4.

Imaging breast cancer using a dual-ligand nanochain particle.

Covarrubias G, Cha A, Rahmy A, Lorkowski M, Perera V, Erokwu BO, Flask C, Peiris PM, Schiemann WP, Karathanasis E.

PLoS One. 2018 Oct 18;13(10):e0204296. doi: 10.1371/journal.pone.0204296. eCollection 2018.

5.

The Kindlin-2 regulation of epithelial-to-mesenchymal transition in breast cancer metastasis is mediated through miR-200b.

Sossey-Alaoui K, Pluskota E, Szpak D, Schiemann WP, Plow EF.

Sci Rep. 2018 May 9;8(1):7360. doi: 10.1038/s41598-018-25373-0.

6.

Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Peiris PM, He F, Covarrubias G, Raghunathan S, Turan O, Lorkowski M, Gnanasambandam B, Wu C, Schiemann WP, Karathanasis E.

Nanoscale. 2018 Apr 19;10(15):6861-6871. doi: 10.1039/c8nr02513d.

7.

Author Correction: Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.

Han Z, Wu X, Roelle S, Chen C, Schiemann WP, Lu ZR.

Nat Commun. 2018 Jan 8;9(1):153. doi: 10.1038/s41467-017-02302-9.

8.

The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer.

Bledzka K, Schiemann B, Schiemann WP, Fox P, Plow EF, Sossey-Alaoui K.

Oncotarget. 2017 Oct 24;8(61):104072-104089. doi: 10.18632/oncotarget.22009. eCollection 2017 Nov 28.

9.

Role of Platinum in Early-Stage Triple-Negative Breast Cancer.

La Belle A, Khatib J, Schiemann WP, Vinayak S.

Curr Treat Options Oncol. 2017 Nov 6;18(11):68. doi: 10.1007/s11864-017-0506-9. Review.

PMID:
29110096
10.

The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence.

Gooding AJ, Zhang B, Jahanbani FK, Gilmore HL, Chang JC, Valadkhan S, Schiemann WP.

Sci Rep. 2017 Oct 5;7(1):12698. doi: 10.1038/s41598-017-12716-6.

11.

TGF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells.

Tian M, Schiemann WP.

J Cancer Metastasis Treat. 2017;3:150-160. doi: 10.20517/2394-4722.2017.38. Epub 2017 Aug 21.

12.

Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.

Han Z, Wu X, Roelle S, Chen C, Schiemann WP, Lu ZR.

Nat Commun. 2017 Sep 25;8(1):692. doi: 10.1038/s41467-017-00741-y. Erratum in: Nat Commun. 2018 Jan 8;9(1):153.

13.

Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1-Mediated Macrophage Infiltration.

Sossey-Alaoui K, Pluskota E, Bialkowska K, Szpak D, Parker Y, Morrison CD, Lindner DJ, Schiemann WP, Plow EF.

Cancer Res. 2017 Sep 15;77(18):5129-5141. doi: 10.1158/0008-5472.CAN-16-2337. Epub 2017 Jul 7.

14.

Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells.

Gooding AJ, Schiemann WP.

Transl Cancer Res. 2016 Aug;5(Suppl 2):S226-S232. doi: 10.21037/tcr.2016.08.09. No abstract available.

15.

Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.

Morrison CD, Chang JC, Keri RA, Schiemann WP.

Cell Death Dis. 2017 Jun 29;8(6):e2899. doi: 10.1038/cddis.2017.294.

16.

The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin.

La Belle AA, Schiemann WP.

Stem Cell Investig. 2017 May 26;4:44. doi: 10.21037/sci.2017.04.07. eCollection 2017. No abstract available.

17.

Oncostatin M activation of Stat3:Smad3 complexes drives senescence.

La Belle AA, Schiemann WP.

Cell Cycle. 2017 Mar 19;16(6):497-498. doi: 10.1080/15384101.2017.1287862. Epub 2017 Jan 27. No abstract available.

18.

Means to the ends: The role of telomeres and telomere processing machinery in metastasis.

Robinson NJ, Schiemann WP.

Biochim Biophys Acta. 2016 Dec;1866(2):320-329. doi: 10.1016/j.bbcan.2016.10.005. Epub 2016 Oct 18. Review.

19.

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.

Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP.

Oncotarget. 2016 Nov 8;7(45):72777-72794. doi: 10.18632/oncotarget.11909.

20.

Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion.

Gupta S, Hau AM, Al-Ahmadie HA, Harwalkar J, Shoskes AC, Elson P, Beach JR, Hussey GS, Schiemann WP, Egelhoff TT, Howe PH, Hansel DE.

Am J Pathol. 2016 May;186(5):1351-60. doi: 10.1016/j.ajpath.2016.01.008. Epub 2016 Mar 14.

21.

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab.

Gollamudi J, Parvani JG, Schiemann WP, Vinayak S.

Cancer Manag Res. 2016 Feb 18;8:21-31. doi: 10.2147/CMAR.S55279. eCollection 2016. Review.

22.

ECO/siRNA nanoparticles and breast cancer metastasis.

Lu ZR, Schiemann WP.

Oncoscience. 2015 Aug 20;2(10):823-4. eCollection 2015. No abstract available.

23.

Non-muscle myosin IIB is critical for nuclear translocation during 3D invasion.

Thomas DG, Yenepalli A, Denais CM, Rape A, Beach JR, Wang YL, Schiemann WP, Baskaran H, Lammerding J, Egelhoff TT.

J Cell Biol. 2015 Aug 17;210(4):583-94. doi: 10.1083/jcb.201502039. Epub 2015 Aug 10.

24.

Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche.

Correa D, Somoza RA, Lin P, Schiemann WP, Caplan AI.

Int J Cancer. 2016 Jan 15;138(2):417-27. doi: 10.1002/ijc.29709. Epub 2015 Aug 17.

25.

Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis.

Doolittle E, Peiris PM, Doron G, Goldberg A, Tucci S, Rao S, Shah S, Sylvestre M, Govender P, Turan O, Lee Z, Schiemann WP, Karathanasis E.

ACS Nano. 2015 Aug 25;9(8):8012-21. doi: 10.1021/acsnano.5b01552. Epub 2015 Jul 28.

26.
27.

Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis.

Peiris PM, Deb P, Doolittle E, Doron G, Goldberg A, Govender P, Shah S, Rao S, Carbone S, Cotey T, Sylvestre M, Singh S, Schiemann WP, Lee Z, Karathanasis E.

J Pharm Sci. 2015 Aug;104(8):2600-10. doi: 10.1002/jps.24518. Epub 2015 Jun 2.

28.

Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.

Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR.

Cancer Res. 2015 Jun 1;75(11):2316-2325. doi: 10.1158/0008-5472.CAN-14-3485. Epub 2015 Apr 9.

29.

Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.

Parvani JG, Davuluri G, Wendt MK, Espinosa C, Tian M, Danielpour D, Sossey-Alaoui K, Schiemann WP.

Neoplasia. 2015 Mar;17(3):317-28. doi: 10.1016/j.neo.2015.02.003.

30.

Therapeutic Opportunities for Targeting microRNAs in Cancer.

Taylor MA, Schiemann WP.

Mol Cell Ther. 2014;2(30):1-13. doi: 10.1186/2052-8426-2-30.

31.

The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.

Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, Schiemann WP.

Neoplasia. 2015 Jan;17(1):124-33. doi: 10.1016/j.neo.2014.11.009.

32.

Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples.

Janyasupab M, Lee YH, Zhang Y, Liu CW, Cai J, Popa A, Samia AC, Wang KW, Xu J, Hu CC, Wendt MK, Schiemann BJ, Thompson CL, Yen Y, Schiemann WP, Liu CC.

Recent Pat Biomark. 2015;5(2):93-100. doi: 10.2174/2210309005666150804195033.

33.

WAVE3-NFκB interplay is essential for the survival and invasion of cancer cells.

Davuluri G, Augoff K, Schiemann WP, Plow EF, Sossey-Alaoui K.

PLoS One. 2014 Oct 16;9(10):e110627. doi: 10.1371/journal.pone.0110627. eCollection 2014.

34.

STAT3 and epithelial-mesenchymal transitions in carcinomas.

Wendt MK, Balanis N, Carlin CR, Schiemann WP.

JAKSTAT. 2014 Jan 1;3(1):e28975. doi: 10.4161/jkst.28975. Epub 2014 Apr 29. Review.

35.

Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.

Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, Schiemann WP.

Breast Cancer Res. 2014 Mar 11;16(2):R24. doi: 10.1186/bcr3623.

36.

Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.

Davuluri G, Schiemann WP, Plow EF, Sossey-Alaoui K.

JAKSTAT. 2015 Feb 3;3(4):e1009276. doi: 10.1080/21623996.2015.1009276. eCollection 2014.

37.
38.

Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development.

Holtzhausen A, Golzio C, How T, Lee YH, Schiemann WP, Katsanis N, Blobe GC.

FASEB J. 2014 Mar;28(3):1248-67. doi: 10.1096/fj.13-239178. Epub 2013 Dec 5.

39.

Longitudinal Bioluminescent Quantification of Three Dimensional Cell Growth.

Wendt MK, Schiemann WP.

Bio Protoc. 2013 Dec 5;3(23). pii: e993.

40.

Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells.

Taylor MA, Davuluri G, Parvani JG, Schiemann BJ, Wendt MK, Plow EF, Schiemann WP, Sossey-Alaoui K.

Breast Cancer Res Treat. 2013 Nov;142(2):341-53. doi: 10.1007/s10549-013-2753-1. Epub 2013 Nov 7.

41.

Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle.

Peiris PM, Toy R, Abramowski A, Vicente P, Tucci S, Bauer L, Mayer A, Tam M, Doolittle E, Pansky J, Tran E, Lin D, Schiemann WP, Ghaghada KB, Griswold MA, Karathanasis E.

J Control Release. 2014 Jan 10;173:51-8. doi: 10.1016/j.jconrel.2013.10.031. Epub 2013 Nov 2.

42.

Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.

Parvani JG, Galliher-Beckley AJ, Schiemann BJ, Schiemann WP.

Mol Biol Cell. 2013 Nov;24(21):3449-59. doi: 10.1091/mbc.E12-10-0776. Epub 2013 Sep 4. Erratum in: Mol Biol Cell. 2014 Feb;25(4):548.

43.
44.

Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, Carlin CR.

J Biol Chem. 2013 Jun 21;288(25):17954-67. doi: 10.1074/jbc.M113.475277. Epub 2013 May 7.

45.

The relevance of the TGF-β Paradox to EMT-MET programs.

Morrison CD, Parvani JG, Schiemann WP.

Cancer Lett. 2013 Nov 28;341(1):30-40. doi: 10.1016/j.canlet.2013.02.048. Epub 2013 Mar 5. Review.

46.

TGF-β upregulates miR-181a expression to promote breast cancer metastasis.

Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP.

J Clin Invest. 2013 Jan;123(1):150-63. doi: 10.1172/JCI64946. Epub 2012 Dec 17.

47.

TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.

Wendt MK, Schiemann BJ, Parvani JG, Lee YH, Kang Y, Schiemann WP.

Oncogene. 2013 Apr 18;32(16):2005-15. doi: 10.1038/onc.2012.230. Epub 2012 Jun 18.

48.

Role of TGF-β and the tumor microenvironment during mammary tumorigenesis.

Taylor MA, Lee YH, Schiemann WP.

Gene Expr. 2011;15(3):117-32. Review.

49.

In vivo dual substrate bioluminescent imaging.

Wendt MK, Molter J, Flask CA, Schiemann WP.

J Vis Exp. 2011 Oct 11;(56). pii: 3245. doi: 10.3791/3245.

50.

NetSlim: high-confidence curated signaling maps.

Raju R, Nanjappa V, Balakrishnan L, Radhakrishnan A, Thomas JK, Sharma J, Tian M, Palapetta SM, Subbannayya T, Sekhar NR, Muthusamy B, Goel R, Subbannayya Y, Telikicherla D, Bhattacharjee M, Pinto SM, Syed N, Srikanth MS, Sathe GJ, Ahmad S, Chavan SN, Kumar GS, Marimuthu A, Prasad TS, Harsha HC, Rahiman BA, Ohara O, Bader GD, Sujatha Mohan S, Schiemann WP, Pandey A.

Database (Oxford). 2011 Sep 29;2011:bar032. doi: 10.1093/database/bar032. Print 2011.

Supplemental Content

Loading ...
Support Center